Who owns Taysha Gene Therapies, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of TSHA from SEC Form 13F filings across 206 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 206 institutions disclosed 316.7M shares of Taysha Gene Therapies, Inc. worth $1.55B — about 78% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
206
13F holders
$1.55B
value, 2026 filers
78%
of shares outstanding (316.7M sh)
29
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of TSHA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 30.4M | $148.2M | 1.5% | 7.5% | +29.2% |
| 2 | GOLDMAN SACHS GROUP INC | 25.1M | $122.3M | 0.0% | 6.2% | +10.6% |
| 3 | Avoro Capital Advisors LLC | 23.9M | $116.3M | 1.2% | 5.9% | 0.0% |
| 4 | BlackRock, Inc. | 22.7M | $110.3M | 0.0% | 5.6% | +9.5% |
| 5 | Vestal Point Capital, LP | 18.0M | $87.9M | 2.3% | 4.4% | -7.1% |
| 6 | MORGAN STANLEY | 15.7M | $76.6M | 0.0% | 3.9% | -4.6% |
| 7 | RTW INVESTMENTS, LP | 13.6M | $66.0M | 0.7% | 3.3% | 0.0% |
| 8 | FMR LLC | 13.6M | $66.0M | 0.0% | 3.3% | +1.7% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 12.5M | $61.1M | 0.0% | 3.1% | +0.5% |
| 10 | STATE STREET CORP | 11.4M | $55.4M | 0.0% | 2.8% | -0.4% |
| 11 | Siren, L.L.C. | 9.8M | $48.0M | 1.1% | 2.4% | 0.0% |
| 12 | Octagon Capital Advisors LP | 9.7M | $47.2M | 6.3% | 2.4% | 0.0% |
| 13 | MPM BIOIMPACT LLC | 7.3M | $35.4M | 2.6% | 1.8% | +61.4% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 7.0M | $33.9M | 0.0% | 1.7% | +6.1% |
| 15 | D. E. Shaw & Co., Inc. | 6.0M | $29.3M | 0.0% | 1.5% | +37.0% |
| 16 | Polar Capital Holdings Plc | 5.1M | $24.8M | 0.1% | 1.3% | -0.3% |
| 17 | BAKER BROS. ADVISORS LP | 4.0M | $19.5M | 0.1% | 1% | 0.0% |
| 18 | Casdin Capital, LLC | 3.9M | $19.0M | 0.8% | 1% | +20.0% |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 3.8M | $18.6M | 0.0% | 0.9% | -3.8% |
| 20 | Aberdeen Group plc | 3.7M | $18.3M | 0.0% | 0.9% | +61.1% |
| 21 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.3M | $16.3M | 0.0% | 0.8% | +6.5% |
| 22 | Pictet Asset Management Holding SA | 3.3M | $16.1M | 0.0% | 0.8% | +19.6% |
| 23 | CITADEL ADVISORS LLC | 3.3M | $16.0M | 0.0% | 0.8% | +114.1% |
| 24 | ADAR1 Capital Management, LLC | 3.1M | $14.9M | 0.7% | 0.8% | +0.6% |
| 25 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 3.0M | $14.7M | 0.0% | 0.7% | -22.5% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.